文献速递肿瘤 PET/CT

己糖激酶2是HK1阴性、HK2阳性且来源广泛肿瘤的可靶向靶点

Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin.
PubMed 文献 · J Nucl Med · 2018-06-07

该研究通过敲低和敲除HK2,在体外和体内异种移植瘤模型中评估HK2对癌细胞增殖、肿瘤进展及18F-FDG PET信号的作用,并分析癌细胞系百科数据中HK1与HK2的表达。结果显示HK1与HK2在肿瘤中功能冗余,单独HK2抑制仅对HK1阴性、HK2阳性的肿瘤亚群有效。作者认为HK2特异性抑制剂治疗可能仅限于HK1阴性、HK2阳性肿瘤亚群,通过分层可识别可治疗肿瘤。

要点

  • 在同时表达HK1和HK2的癌细胞中,敲低或敲除HK2不抑制细胞增殖或异种移植瘤进展。
  • 在仅表达HK2而不表达HK1的癌细胞中,敲低HK2可抑制细胞增殖、集落形成和异种移植瘤进展。
  • HK1与HK2在肿瘤中功能冗余,单独HK2抑制可能仅对HK1阴性、HK2阳性肿瘤亚群有效。

核心结论

  • HK1与HK2在肿瘤中表达冗余,任一均可为肿瘤生长提供足够的需氧糖酵解,尽管18F-FDG PET信号降低。
  • 治疗性HK2抑制可能仅限于HK1阴性、HK2阳性的肿瘤亚群,但分层表达HK2而不表达HK1的肿瘤应能识别可用新兴HK2特异性抑制剂治疗的肿瘤。

研究设计与样本

  • 采用HK2敲低和敲除方法研究HK2在癌细胞增殖、体内异种移植瘤进展及18F-FDG肿瘤摄取中的作用。
  • BioProfiler分析监测细胞培养的葡萄糖消耗和乳酸生成;18F-FDG PET/CT监测体内肿瘤葡萄糖摄取。
  • 分析癌细胞系百科数据中HK1和HK2的表达。

主要发现

  • 在表达HK1和HK2的癌细胞中,HK2敲低或敲除均不抑制细胞培养中的增殖或异种移植瘤进展。
  • 来自多种组织来源的癌症亚群仅表达HK2而不表达HK1。
  • 与HK1阳性HK2阳性癌症不同,HK1阴性HK2阳性癌细胞中敲低HK2导致细胞增殖、集落形成和异种移植瘤进展受抑制。
  • HK1敲除HK2阳性癌细胞对HK2抑制敏感,而同基因的HK1阳性HK2阳性亲本细胞则不敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although absent in most adult tissues, hexokinase 2 (HK2) is expressed in a majority of tumors and contributes to increased glucose consumption and to in vivo tumor 18F-FDG PET signaling. Methods: Both HK2 knockdown and knockout approaches were used to investigate the role of HK2 in cancer cell proliferation, in vivo xenograft tumor progression and 18F-FDG tumor accumulation. BioProfiler analysis monitored cell culture glucose consumption and lactate production; 18F-FDG PET/CT monitored in vivo tumor glucose accumulation. Cancer Cell Line Encyclopedia data were analyzed for HK1 and HK2 expression. Results: Neither cell proliferation in culture nor xenograft tumor progression are inhibited by HK2 knockdown or knockout in cancer cells that express HK1 and HK2. However, cancer subsets from a variety of tissues of origin express only HK2, but not HK1. In contrast to HK1+HK2+ cancers, HK2 knockdown in HK1-HK2+ cancer cells results in inhibition of cell proliferation, colony formation and xenograft tumor progression. Moreover, HK1KOHK2+ cancer cells are susceptible to HK2 inhibition, in contrast to their isogenic HK1+HK2+ parental cells. Conclusion: HK1 and HK2 expression are redundant in tumors; either can provide sufficient aerobic glycolysis for tumor growth; despite a reduction in 18F-FDG PET signal. Therapeutic HK2 inhibition is likely to be restricted to HK1-HK2+ tumor subsets, but stratification of tumors that express HK2, but not HK1, should identify tumors treatable with emerging HK2 specific inhibitors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xu S, Catapang A, Doh HM, et al. Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin. J Nucl Med. 2018. PMID: 29880505. doi:10.2967/jnumed.118.212365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。